Medical dropper system with bag on tube 3d vector illustration. Advertising poster with laboratory equipment over copy space. Hospital emergency services promotion The human gastrointestinal tract can ...

The FDA has approved golimumab-sldi as the first interchangeable biosimilar to Simponi for ulcerative colitis. Golimumab-sldi (Immgolis, Accord BioPharma) has been approved as a biosimilar to ...

The lowest effective recommended dosage should be used to maintain therapeutic response. The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adult patients ...

ORLANDO -- Vedolizumab (Entyvio) and infliximab (Remicade) led to mostly similar 1-year outcomes in patients with ulcerative colitis previously untreated with a biologic, but the integrin receptor ...

We hope you've had a chance to review the press release we issued after market close in the U.S. today, announcing the positive top-line results of the Phase III ABTECT Maintenance trial. Joining me ...

Credit: Takeda. Entyvio for SC use is expected to be available by the end of October 2023. The Food and Drug Administration (FDA) has approved the subcutaneous (SC) administration of Entyvio ® ...

A medication used for psoriasis and psoriatic arthritis is proving to be an effective treatment for moderate to severe ulcerative colitis in the findings of a global study led by University of Chicago ...

INDIANAPOLIS, Oct. 26, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh™ (mirikizumab-mrkz) infusion (300 ...

− If approved, the additional treatment modality will provide more options for how patients in Europe receive the gut-selective biologic vedolizumab − Recommendation brings vedolizumab one step closer ...

The Digestive Health Physicians Association issued a statement opposing CMS’ Most Favored Nation rule because it potentially limits access to infusion services. If the rule goes into effect, the ...